Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model

International Journal of Molecular Medicine

Volumn 27, Issue 6, 2011, Pages 775-781

  Dȩbiński, Marcin ^a   Buszman, Piotr P ^a   Milewski, Krzysztof ^a,c   Wojakowski, Wojciech ^a,b   Jackiewicz, Wanda ^a   Paja̧k, Jacek ^b   Szurlej, Dariusz ^b   Fryc Stanek, Joanna ^b   Wiernek, Szymon ^a,d   Jelonek, Michal ^a   Spurlock, Michael E ^e   Martin, Jack ^f   Bochenek, Andrzej ^a,b   Buszman, Pawel E ^a  

^a American Heart of Poland   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^d San Antonio Endovascular and Heart Institute   (United States)

^e IOWA STATE UNIVERSITY   (United States)

^f BRYN MAWR HOSPITAL   (United States)

Author keywords

Adiponectin; Ischemia; Myocardial infarction; Porcine; Reperfusion injury

Indexed keywords

ADIPONECTIN; EVANS BLUE; TROPONIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFUSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ADIPONECTIN; ANIMALS; FEMALE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; SUS SCROFA; TIME FACTORS;

EID: 79954493068     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.643     Document Type: Article

References (30)

1. Rogers WJ, Canto JG, Lambrew CT, et al: Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 36: 2056-2063, 2000.
2. Zahn R, Schiele R, Schneider S, et al: Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 36: 2064-2071, 2000.
3. Mehran R, Brodie B, Cox DA, et al: The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 156: 44-56, 2008. (Pubitemid 351862292)
4. Spencer FA, Meyer TE, Gore JM and Goldberg RJ: Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 105: 2605-2610, 2002. (Pubitemid 34596036)
5. Vaur L, Danchin N, Genes N, et al: Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J 137: 49-58, 1999. (Pubitemid 29038362)
6. Levy D, Kenchaiah S, Larson MG, et al: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397-1402, 2002.
7. Park JL and Lucchesi BR: Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 68: 1905-1912, 1999.
8. Yellon DM and Hausenloy DJ: Myocardial reperfusion injury: N Engl J Med 357: 1121-1135, 2007.
9. Braunwald E and Kloner RA: Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719, 1985.
10. Piper HM, Meuter K and Schafer C: Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75: 644-648, 2003.
11. Ross AM, Gibbons RJ, Stone GW, Kloner RA and Alexander RW: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775-1780, 2005. (Pubitemid 40779856)
12. Bates E, Bode C, Costa M, et al: Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117: 886-896, 2008. (Pubitemid 351272586)
13. Cheng KK, Lam KS, Wang Y, et al: Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56: 1387-1394, 2007. (Pubitemid 46715600)
14. Motoshima H, Wu X, Mahadev K and Goldstein BJ: Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315: 264-271, 2004. (Pubitemid 38183103)
15. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M and Kohno N: A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. Metabolism 54: 194-199, 2005. (Pubitemid 40174847)
16. Ouedraogo R, Gong Y, Berzins B, et al: Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 117: 1718-1726, 2007. (Pubitemid 46871356)
17. Kobayashi H, Ouchi N, Kihara S, et al: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: 27-31, 2004.
18. Shibata R, Sato K, Pimentel DR, et al: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11: 1096-1103, 2005. (Pubitemid 41486832)
19. Kondo K, Shibata R, Unno K, et al: Impact of a single intracoronary administration of adiponectin on myocardial ischemia/reperfusion injury in a pig model. Circ Cardiovasc Interv 3: 166-174, 2010.
20. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y and Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14: 561-566, 2003. (Pubitemid 41623184)
21. Ouchi N, Kihara S, Funahashi T, et al: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107: 671-674, 2003. (Pubitemid 36222590)
22. Suzuki Y, Lyons JK, Yeung AC and Ikeno F: In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc Interv 71: 100-107, 2008.
23. Zweier JL, Flaherty JT, Weisfeldt ML: Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA 84: 1404-1407, 1987. (Pubitemid 17027362)
24. Arroyo CM, Kramer JH, Dickens BF and Weglicki WE: Identification of free radicals in myocardial ischemia/reperfusion by spin trapping with nitrone DMPO. FEBS Lett 221: 101-104, 1987.
25. Iwashima Y, Katsuya T, Ishikawa K, et al: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43: 1318-1323, 2004. (Pubitemid 38691756)
26. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999. (Pubitemid 29299050)
27. Furukawa S, Fujita T, Shimabukuro M, et al: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004. (Pubitemid 40385531)
28. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000. (Pubitemid 30353893)
29. Bolli R BL, Gross G, Mentzer R Jr, Balshaw D and Lathrop DA: Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95: 125-134, 2004. (Pubitemid 38988678)
30. Baxter GF, Hale SL, Miki T, et al: Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14: 607-614, 2000. (Pubitemid 32217183)